Tenaya Therapeutics takes in $106m
GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.
Connect Bio to attach itself to public markets
Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.
Oxular eyes $37m round
Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.
Carisma charms its way to $59m
Penn Medicine contributed to a $12m extension for the cancer immunotherapy developer's series B round, which already inlcuded Livzon, Merck & Co and AbbVie.
MDLive heads to Evernorth
Sutter Health, Novo, Sentara and Health Care Service Corporation are set to exit the virtual healthcare provider in an acquisition of undisclosed size.
PharmEasy sells stake to CDPQ
The pension fund will pay an undisclosed sum for a 2% stake in API Holdings, the owner of online drugstore PharmEasy backed by Ascent Health and Medi Assist.
AstraZeneca achieves Moderna stake sale
AstraZeneca likely received over $1bn from selling its shares, having invested $140m in the publicly listed covid-19 vaccine developer in 2015.
Xilio seals $95m series C round
Returning corporate investors Takeda Ventures and MRL Ventures Fund helped the cancer immunotherapy developer take its total funding to over $225m.

Other News

Artiva cleaves $120m in series B round
GC and its GC LabCell subsidiary both contributed to a round that will help advance the cancer immunotherapy developer's NK cell drug pipeline.
AnchorDX holds down $40m of series C funding
The KingMed Diagnostics and WuXi AppTec-backed cancer diagnosis technology developer intends to use the series C funding to bring its products to market.
Corporate venturing deal net: 22-26 February 2021
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Clover discovers $230m in series C funding
The Jinlong Group-backed biologic drug developer’s latest round pushed its overall funding from the past 12 months to approximately $387m.
Innovaccer vacuums up $105m
Microsoft unit M12 backed the healthcare data software provider in a round that valued the latter at $1.3bn, pushing its overall funding past $225m.
Lyvgen generates series C funding
IDG Capital has led a round, sized at hundreds of millions of yuan, for the 6 Dimensions Capital-backed cancer therapeutics developer.

Editor's Picks

23andMe links to Virgin in $3.5bn reverse merger
The corporate-backed genetic testing service is joining forces with an NYSE-listed special purpose acquisition company sponsored by Virgin Group.
Sana Bio plants itself on public markets
The Alphabet-backed immunotherapy developer secured nearly $588m in what was reputedly the largest ever flotation for a preclinical life sciences company.
2021 in Corporate Venturing: A Preview
Micromobility, AI-equipped drug discovery, home fitness and cloud kitchens are among the sectors that look promising in 2021.
CVC in 2020: The Trends, Part Two
In the second half of out 2020 roundup we look at growth areas including digital health and health insurance, online education platforms and financial technology.
test reg